Natco Pharma invests around $2 million in Cellogen Therapeutics

17 Jan 2024 Evaluate

Natco Pharma has invested around $2 million in Cellogen Therapeutics to support development of affordable cell and gene therapies in India. Cellogen is primarily involved in two R&D programs involving cell and gene therapy solutions. Chimeric Antigen Receptor T (CAR T) cell therapy program is at an advanced stage for Cellogen Therapeutics where the T cells of the patients are genetically engineered to identify and kill the cancer cells. 

Cellogen Therapeutics has developed bi-specific CARs and also added another costimulatory domain to increase the efficacy and persistence of the CAR in human body as compared to currently available CAR constructs that are mono-specific with one co-stimulatory domain. Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy which remains a major challenge with existing CAR constructs. Current available products in market cost around $500,000 - 700,000 which Cellogen aims to bring down to $60,000 - 70,000.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

826.85 -0.25 (-0.03%)
17-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1751.05
Dr. Reddys Lab 1163.70
Cipla 1515.45
Lupin 1936.75
Zydus Lifesciences 831.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...